Castle Biosciences Announces Publication Of New Study Highlighting Demand For Molecular Testing In Atopic Dermatitis

Castle Biosciences, Inc. (NASDAQ: CSTL) announced the publication of a study revealing that over half of patients using targeted systemic therapies for atopic dermatitis modified their treatment due to ineffectiveness. The study found that 94% of patients open to new systemic therapies expressed interest in molecular testing to identify more effective treatments. The findings underscore the clinical need for molecular guidance in atopic dermatitis care, which Castle's AdvanceAD-Tx test aims to address by personalizing therapy decisions based on individual disease biology.